Head-to-head · WeighScore
ShedRx vs Ro
The verdict
ShedRx takes it — 88/100 to 78/100.
ShedRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. The widest formulation spread on the board — oral/sublingual routes plus standard injection.
Partner links are labeled — we may earn a commission at no cost to you. It never changes the grade.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | ShedRx | Ro |
|---|---|---|
| WeighScore | 88/100 | 78/100 |
| Grade | B+ | C+ |
| Scorecard rank | #3 | #24 |
| Semaglutide | $199/mo | Not disclosed |
| Tirzepatide | $299/mo | Not disclosed |
| Coverage | Not disclosed | Multi-state |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Yes | Yes |
| Relationship | Partner | Editorial |
Graded #3 · B+
Strengths
- Oral/sublingual options
- Competitive tirzepatide pricing
- Strong dose flexibility
Where it loses points
- States-served not disclosed
- Compounded only
Graded #24 · C+
Strengths
- Brand-name access + insurance support
- Oral options
- Well-funded platform
Where it loses points
- Does not disclose compounded pricing up front
- Premium positioning
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 25 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.